AI Drug Discovery: Insilico, Broad, and Novo Nordisk Lead

Insilico's rentosertib shows dose-dependent FVC improvement in IPF Phase IIa; $165M CNS deal. Broad Institute launches GaMBiT initiative for genetics-to-therapies translation. Novo Nordisk partners with AWS for AI drug discovery, establishing London AI hub. Nucleai and Gilead expand AI-powered tissue analytics collaboration for ADC biomarker discovery.